$GTHP
GUIDED THERAPEUTICS INC Stock $gthp

$gthp Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000147793222006064 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$3.000K	$5.000K	$5.000K
YoY Change	-84.21%	150.0%
Cost Of Revenue	$0.00	$1.000K	$1.000K
YoY Change	-100.0%
Gross Profit	$3.000K	$4.000K	$4.000K
YoY Change	-113.04%	100.0%
Gross Profit Margin	100.0%	80.0%	80.0%
Selling, General & Admin	$1.219M	$712.0K	$426.0K
YoY Change	172.1%	31.12%	-47.21%
% of Gross Profit	40633.33%	17800.0%	10650.0%
Research & Development	$8.000K	$9.000K	$21.00K
YoY Change	-50.0%	-55.0%	31.25%
% of Gross Profit	266.67%	225.0%	525.0%
Depreciation & Amortization	$1.000K	$0.00	$0.00
YoY Change	0.0%
% of Gross Profit	33.33%	0.0%	0.0%
Operating Expenses	$1.227M	$721.0K	$447.0K
YoY Change	164.44%	28.06%	-45.69%
Operating Profit	-$1.224M	-$717.0K	-$443.0K
YoY Change	151.33%	27.81%	-46.17%
Interest Expense	$155.0K	$256.0K	$101.0K
YoY Change	-73.91%	-18.73%	-28.37%
% of Operating Profit
Other Income/Expense, Net	$122.0K	-$209.0K	$2.000K
YoY Change	-78.02%	-55.81%
Pretax Income	-$1.102M	-$926.0K	-$507.0K
YoY Change	-1720.59%	-10.44%	-1.93%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	$1.102M	-$926.0K	-$507.0K
YoY Change	1520.59%	-10.44%	-1.93%
Net Earnings / Revenue	36733.33%	-18520.0%	-10140.0%
Basic Earnings Per Share	-$0.03	-$0.04	-$0.05
Diluted Earnings Per Share	-$0.03	-$0.04	-$0.05
COMMON SHARES
Basic Shares Outstanding	36.66M shares	27.57M shares
Diluted Shares Outstanding	34.83M shares	26.34M shares	20.68M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.697M	$446.0K	$725.0K
YoY Change	398.52%	-51.63%	-41.86%
Cash & Equivalents	$2.697M	$446.0K	$725.0K
Short-Term Investments
Other Short-Term Assets	$169.0K	$59.00K	$453.0K
YoY Change	-2.31%	-3.28%	1061.54%
Inventory	$596.0K	$569.0K	$570.0K
Prepaid Expenses
Receivables	$29.00K	$29.00K	$39.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$3.491M	$1.103M	$1.787M
YoY Change	162.88%	-32.74%	-6.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$42.00K	$45.00K	$28.00K
YoY Change	281.82%	542.86%	-93.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$17.00K	$17.00K	$17.00K
YoY Change	0.0%	0.0%	-5.56%
Total Long-Term Assets	$380.0K	$400.0K	$400.0K
YoY Change	-8.65%	-6.32%	-10.31%
TOTAL ASSETS
Total Short-Term Assets	$3.491M	$1.103M	$1.787M
Total Long-Term Assets	$380.0K	$400.0K	$400.0K
Total Assets	$3.871M	$1.503M	$2.187M
YoY Change	121.96%	-27.29%	-7.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.217M	$2.404M	$2.556M
YoY Change	-0.14%	0.88%	-0.31%
Accrued Expenses	$1.050M	$1.206M	$999.0K
YoY Change	3087.13%	-30.33%	-78.73%
Deferred Revenue
YoY Change
Short-Term Debt	$686.0K	$378.0K	$788.0K
YoY Change	-20.33%	-65.42%	-39.2%
Long-Term Debt Due	$32.00K	$47.00K	$67.00K
YoY Change	77.78%	95.83%	-72.65%
Total Short-Term Liabilities	$5.146M	$5.996M	$5.449M
YoY Change	1.38%	5.73%	-40.96%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$986.0K	$1.420M
YoY Change	-100.0%	-26.09%	145.25%
Other Long-Term Liabilities	$267.0K	$287.0K	$307.0K
YoY Change	-28.42%	-25.65%	-37.22%
Total Long-Term Liabilities	$1.376M	$1.273M	$1.727M
YoY Change	-21.19%	-25.99%	61.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.146M	$5.996M	$5.449M
Total Long-Term Liabilities	$1.376M	$1.273M	$1.727M
Total Liabilities	$6.522M	$7.269M	$7.176M
YoY Change	-4.4%	-1.65%	-30.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$145.5M	-$144.4M	-$143.4M
YoY Change	2.55%	1.85%
Common Stock	$3.432M	$3.416M	$3.410M
YoY Change	0.85%	0.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$132.0K	$132.0K
YoY Change	0.0%
Treasury Stock Shares
Shareholders Equity	-$2.651M	-$5.766M	-$4.988M
YoY Change
Total Liabilities & Shareholders Equity	$3.871M	$1.503M	$2.187M
YoY Change	121.96%	-27.29%	-7.41%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	$1.102M	-$926.0K	-$507.0K
YoY Change	1520.59%	-10.44%	-1.93%
Depreciation, Depletion And Amortization	$1.000K	$0.00	$0.00
YoY Change	0.0%
Cash From Operating Activities	-$612.0K	-$349.0K	-$179.0K
YoY Change	-17.19%	-73.46%	-44.06%
INVESTING ACTIVITIES
Capital Expenditures	$3.000K	-$17.00K	$14.00K
YoY Change	-160.0%	325.0%	1300.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$3.000K	-$17.00K	-$14.00K
YoY Change	-160.0%	325.0%	1300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.860M	87.00K	$275.0K
YoY Change	687.88%	-91.25%	-80.16%
NET CHANGE
Cash From Operating Activities	-612.0K	-349.0K	-$179.0K
Cash From Investing Activities	3.000K	-17.00K	-$14.00K
Cash From Financing Activities	2.860M	87.00K	$275.0K
Net Change In Cash	2.251M	-279.0K	$82.00K
YoY Change	-690.81%	-14.15%	-92.3%
FREE CASH FLOW
Cash From Operating Activities	-$612.0K	-$349.0K	-$179.0K
Capital Expenditures	$3.000K	-$17.00K	$14.00K
Free Cash Flow	-$615.0K	-$332.0K	-$193.0K
YoY Change	-16.21%	-74.68%	-39.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000924515
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2021Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	126000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	785000	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27583000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13673000	shares
CY2021Q4	gthp	Common Stock Shares Authorized Shares CommonStockSharesAuthorizedShares	500000000	shares
CY2021Q4	gthp	Common Stocks Shares Outstanding CommonStocksSharesOutstanding	13673583	shares
CY2022Q2	gthp	Common Stocks Shares Outstanding CommonStocksSharesOutstanding	27583473	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.49
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
	gthp	Options Granted Expiration Term OptionsGrantedExpirationTerm	P10Y
	gthp	Options Granted Exercisable Term OptionsGrantedExercisableTerm	P4Y
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	0	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Entity File Number EntityFileNumber	0-22179
	dei	Entity Registrant Name EntityRegistrantName	GUIDED THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	58-2029543
	dei	Entity Address Address Line1 EntityAddressAddressLine1	5835 Peachtree Corners East
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite B
	dei	Entity Address City Or Town EntityAddressCityOrTown	Norcross
	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30092
	dei	City Area Code CityAreaCode	770
	dei	Local Phone Number LocalPhoneNumber	242-8723
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	36664707	shares
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2040000	usd
	us-gaap	Revenues Revenues	10000	usd
	us-gaap	Revenues Revenues	2000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1000	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	4000	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	0	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	22000	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27583000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13673000	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	3416000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	3403000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	130166000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	126800000	usd
CY2022Q2	us-gaap	Treasury Stock Value TreasuryStockValue	132000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	132000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-144448000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-142387000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5766000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5445000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1503000	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	2000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36000	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	37000	usd
CY2021Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	30000	usd
	gthp	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	0	usd
	gthp	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	448000	usd
CY2022Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-1000	usd
CY2021Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	27000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	4000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	27000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-209000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-717000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-561000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1162000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1440000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	256000	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	315000	usd
	us-gaap	Interest Expense InterestExpense	357000	usd
	us-gaap	Interest Expense InterestExpense	456000	usd
CY2022Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	14000	usd
CY2021Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	8000	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-88000	usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	34000	usd
CY2021Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-185000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	75000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-185000	usd
CY2022Q2	gthp	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	0	usd
CY2021Q2	gthp	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	0	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	77000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	66000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	675000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	513000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1062000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1340000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	721000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	563000	usd
	us-gaap	Operating Expenses OperatingExpenses	1170000	usd
	us-gaap	Operating Expenses OperatingExpenses	1442000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-473000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-270000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-254000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-926000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1034000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1432000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1694000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-926000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1034000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1432000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1694000	usd
CY2022Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	81000	usd
CY2021Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	125000	usd
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	629000	usd
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	177000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1007000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1159000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2061000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1871000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
	gthp	Issuance Of Common Stock For Payment Of Series F2 Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesF2PreferredDividendsAmount	75000	usd
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2022Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	26337000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	13280000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	23526000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	13226000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26337000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13280000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23526000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13226000	shares
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-4988000	usd
CY2022Q2	gthp	Common Stock Warrants Exercised CommonStockWarrantsExercised	130000	usd
CY2022Q2	gthp	Issuance Of Common Stock For Payment Of Series D Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesDPreferredDividendsAmount	13000	usd
CY2022Q2	gthp	Issuance Of Common Stock For Payment Of Series E Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesEPreferredDividendsAmount	26000	usd
CY2022Q2	gthp	Issuance Of Common Stock For Payment Of Series F Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesFPreferredDividendsAmount	2000	usd
CY2022Q2	gthp	Issuance Of Common Stock For Payment Of Series F2 Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesF2PreferredDividendsAmount	12000	usd
CY2022Q2	gthp	Conversion Of Series D Preferred Stock To Common Stock Amount ConversionOfSeriesDPreferredStockToCommonStockAmount	1000	usd
CY2022Q2	gthp	Conversion Of Series E Preferred Stock To Common Stock Amount ConversionOfSeriesEPreferredStockToCommonStockAmount	0	usd
CY2022Q2	gthp	Conversionofseriesfpreferredstocktocommonstock Amount ConversionofseriesfpreferredstocktocommonstockAmount	1000	usd
CY2022Q2	gthp	Conversion Of Series F2 Preferred Stock To Common Stockamount ConversionOfSeriesF2PreferredStockToCommonStockamount	0	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	44000	usd
CY2022Q2	gthp	Accrued Preferred Dividends AccruedPreferredDividends	-8000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-926000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-5766000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-5445000	usd
	gthp	Common Stock Warrants Exercised Amount CommonStockWarrantsExercisedAmount	846000	usd
	gthp	Issuance Of Common Stock For Payment Of Series D Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesDPreferredDividendsAmount	29000	usd
	gthp	Issuance Of Common Stock For Payment Of Series E Preferred Dividends IssuanceOfCommonStockForPaymentOfSeriesEPreferredDividends	34000	usd
	gthp	Issuance Of Common Stock For Payment Of Series F Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesFPreferredDividendsAmount	107000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2000	usd
	gthp	Issuance Of Common Stock For Payment Of Interest Amount IssuanceOfCommonStockForPaymentOfInterestAmount	81000	usd
	gthp	Issuance Of Common Stock For Series F And Series F2 One Time15 Dividends Amount IssuanceOfCommonStockForSeriesFAndSeriesF2OneTime15DividendsAmount	400000	usd
	gthp	Conversion Of Series D Preferred Stock To Common Stock Amount ConversionOfSeriesDPreferredStockToCommonStockAmount	1000	usd
	gthp	Conversion Of Series E Preferred Stock To Common Stock Amount ConversionOfSeriesEPreferredStockToCommonStockAmount	0	usd
	gthp	Conversion Of Series F Preferred Stock To Common Stock Amount ConversionOfSeriesFPreferredStockToCommonStockAmount	0	usd
	gthp	Conversion Of Series F2 Preferred Stock To Common Stock Amount ConversionOfSeriesF2PreferredStockToCommonStockAmount	0	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	88000	usd
	gthp	Expense For Warrants Issued To Consultants ExpenseForWarrantsIssuedToConsultants	79000	usd
	gthp	Accrued Preferred Dividends AccruedPreferredDividends	-629000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1432000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-7992000	usd
CY2021Q2	gthp	Series F Preferred Offering SeriesFPreferredOffering	0	usd
CY2021Q2	gthp	Series F2 Preferred Offering Amount SeriesF2PreferredOfferingAmount	404000	usd
CY2021Q2	gthp	Conversion Of Debt And Expenses For Series F2 Preferred Stock ConversionOfDebtAndExpensesForSeriesF2PreferredStock	2559000	usd
CY2021Q2	gthp	Issuance Of Common Stock For Series D Preferred Dividends Amount IssuanceOfCommonStockForSeriesDPreferredDividendsAmount	14000	usd
CY2021Q2	gthp	Series G Redemption Amount SeriesGRedemptionAmount	0	usd
CY2021Q2	gthp	Issuance Of Common Stock To Finders Amount IssuanceOfCommonStockToFindersAmount	54000	usd
CY2021Q2	gthp	Issuance Of Warrants To Consultants IssuanceOfWarrantsToConsultants	736000	usd
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	60000	usd
CY2021Q2	gthp	Accrued Preferred Dividends AccruedPreferredDividends	-125000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1034000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-5324000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-10855000	usd
	gthp	Series F Preferred Offering Amount SeriesFPreferredOfferingAmount	1195000	usd
	gthp	Series F2 Preferred Offering Amount SeriesF2PreferredOfferingAmount	404000	usd
	gthp	Conversion Of Debt And Expenses For Series F2 Preferred Stock Amount ConversionOfDebtAndExpensesForSeriesF2PreferredStockAmount	2559000	usd
	gthp	Issuance Of Common Stock For Series D Preferred Dividends Amount IssuanceOfCommonStockForSeriesDPreferredDividendsAmount	28000	usd
	gthp	Series G Preferred Offering Amount SeriesGPreferredOfferingAmount	0	usd
	gthp	Series G Redemption Amount SeriesGRedemptionAmount	0	usd
	gthp	Issuance Of Common Stock To Finders Amount IssuanceOfCommonStockToFindersAmount	54000	usd
	gthp	Issuance Of Warrants To Consultants IssuanceOfWarrantsToConsultants	1285000	usd
	gthp	Conversions Of Warrants From Liability To Equity ConversionsOfWarrantsFromLiabilityToEquity	1755000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	122000	usd
	gthp	Accrued Preferred Dividends AccruedPreferredDividends	-177000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1694000	usd
	us-gaap	Profit Loss ProfitLoss	-1432000	usd
	us-gaap	Profit Loss ProfitLoss	-1694000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	78000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	236000	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	8000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	88000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	122000	usd
	gthp	Increase Decrease In Fair Value Of Warrants IncreaseDecreaseInFairValueOfWarrants	0	usd
	gthp	Increase Decrease In Fair Value Of Warrants IncreaseDecreaseInFairValueOfWarrants	-448000	usd
	gthp	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	-8000	usd
	gthp	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	88000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	33000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	0	usd
	gthp	Expense For Warrants Issued To Consultants ExpenseForWarrantsIssuedToConsultants	79000	usd
	gthp	Expense For Warrants Issued To Consultants ExpenseForWarrantsIssuedToConsultants	477000	usd
	gthp	Gain Loss From Forgiveness Of Debt GainLossFromForgivenessOfDebt	-75000	usd
	gthp	Gain Loss From Forgiveness Of Debt GainLossFromForgivenessOfDebt	185000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	157000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	16000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-26000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	317000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	24000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-17000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	74000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	15000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-32000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	175000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	20000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-528000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1012000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	495000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	gthp	Payments Made On Notes Payable PaymentsMadeOnNotesPayable	-133000	usd
	gthp	Payments Made On Notes Payable PaymentsMadeOnNotesPayable	-1368000	usd
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0	usd
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	1044000	usd
	gthp	Note Payable Default Penalty NotePayableDefaultPenalty	0	usd
	gthp	Note Payable Default Penalty NotePayableDefaultPenalty	56000	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1436000	usd
	gthp	Proceeds From Series F2 Offering Net Of Costs ProceedsFromSeriesF2OfferingNetOfCosts	0	usd
	gthp	Proceeds From Series F2 Offering Net Of Costs ProceedsFromSeriesF2OfferingNetOfCosts	539000	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	125000	usd
	gthp	Redemption Of Series G Preferred Stock RedemptionOfSeriesGPreferredStock	0	usd
	gthp	Redemption Of Series G Preferred Stock RedemptionOfSeriesGPreferredStock	75000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	362000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1757000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-197000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	740000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	643000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	182000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	446000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	922000	usd
	us-gaap	Interest Paid InterestPaid	14000	usd
	us-gaap	Interest Paid InterestPaid	541000	usd
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	629000	usd
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	177000	usd
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	81000	shares
	gthp	Issuance Of Series F2 Preferred Stock IssuanceOfSeriesF2PreferredStock	0	usd
	gthp	Issuance Of Series F2 Preferred Stock IssuanceOfSeriesF2PreferredStock	2559000	usd
	gthp	Issuance Of Warrants To Finders In Connection With Series F And Series F2 Preferred Stock IssuanceOfWarrantsToFindersInConnectionWithSeriesFAndSeriesF2PreferredStock	0	usd
	gthp	Issuance Of Warrants To Finders In Connection With Series F And Series F2 Preferred Stock IssuanceOfWarrantsToFindersInConnectionWithSeriesFAndSeriesF2PreferredStock	377000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	646000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	31000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	24000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1755000	usd
	gthp	Conversion Of Series D Preferred Shares Into Common Stock ConversionOfSeriesDPreferredSharesIntoCommonStock	118000	usd
	gthp	Conversion Of Series D Preferred Shares Into Common Stock ConversionOfSeriesDPreferredSharesIntoCommonStock	0	usd
	gthp	Conversion Of Series E Preferred Shares Into Common Stock ConversionOfSeriesEPreferredSharesIntoCommonStock	800000	usd
	gthp	Conversion Of Series E Preferred Shares Into Common Stock ConversionOfSeriesEPreferredSharesIntoCommonStock	0	usd
CY2022Q2	us-gaap	Derivative Liability Notional Amount DerivativeLiabilityNotionalAmount	400000	usd
	gthp	Conversion Of Series F Preferred Shares Into Common Stock ConversionOfSeriesFPreferredSharesIntoCommonStock	296000	usd
	gthp	Conversion Of Series F Preferred Shares Into Common Stock ConversionOfSeriesFPreferredSharesIntoCommonStock	0	usd
	gthp	Conversion Of Series F2 Preferred Shares Into Common Stock ConversionOfSeriesF2PreferredSharesIntoCommonStock	426000	usd
	gthp	Conversion Of Series F2 Preferred Shares Into Common Stock ConversionOfSeriesF2PreferredSharesIntoCommonStock	0	usd
	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. </strong><strong>ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Guided Therapeutics, Inc. (formerly SpectRx, Inc.), together with its wholly owned subsidiary, InterScan, Inc. (formerly Guided Therapeutics, Inc.), collectively referred to herein as the “Company“, is a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. The Company’s primary focus is the continued commercialization of its LuViva non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, including esophageal. The Company’s technology, including products in research and development, primarily relates to biophotonics technology for the non-invasive detection of cancers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2021, the Board simultaneously approved a 1-for-20 reverse stock split of our common stock and decreased the total number of authorized common shares to 500,000,000. On November 18, 2021, the Company submitted an Issuer Company Related Action Notification regarding the reverse stock split to the Financial Industry Regulatory Authority (“FINRA“). On July 25, 2022, the Company filed a Certificate of Correction with the Secretary of State of Delaware to render null and void <em>ab initio</em> the Reverse Split Amendment and as a result, the Reverse Split was deemed null and void.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Basis of Presentation </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP“) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC“) pursuant to Section 13 or 15(d) under the Securities Exchange Act of 1934. The December 31, 2021 balances reported herein are derived from the audited consolidated financial statements for the year ended December 31, 2021. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the Company as of June 30, 2022 and December 31, 2021, and the consolidated results of operations and cash flows for the three and six-month periods ended June 30, 2022 and 2021 have been included.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. The Company has experienced net losses since its inception and, as of June 30, 2022, it had an accumulated deficit of approximately $144.4 million. To date, the Company has engaged primarily in research and development efforts and the early stages of marketing its products. The Company may not be successful in growing sales for its products. Moreover, required regulatory clearances or approvals may not be obtained in a timely manner, or at all. The Company’s products may not ever gain market acceptance and the Company may not ever generate significant revenues or achieve profitability. The development and commercialization of the Company’s products requires substantial development, regulatory, sales and marketing, manufacturing and other expenditures. The Company expects operating losses to continue for the foreseeable future as it continues to expend substantial resources to complete development of its products, obtain regulatory clearances or approvals, build its marketing, sales, manufacturing and finance capabilities, and conduct further research and development.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is not organized by multiple operating segments for the purpose of making operating decisions or assessing performance. Accordingly, the Company operates in one reportable operating segment. The Company’s principal decision makers are the Chief Executive Officer and its Chief Financial Officer. Management believes that its business operates as one reportable segment because: a) the Company measures profit and loss as a whole; b) the principal decision makers do not review information based on any operating segment; c) the Company does not maintain discrete financial information on any specific segment; d) the Company has not chosen to organize its business around different products and services, and e) the Company has not chosen to organize its business around geographic areas.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Going Concern</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. The factors below raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">At June 30, 2022, the Company had a negative working capital of approximately $4.9 million, accumulated deficit of $144.4 million, and incurred a net loss including preferred dividends of $2.1 million for the six months then ended. Stockholders’ deficit totaled approximately $5.8 million at June 30, 2022, primarily due to recurring net losses from operations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the six-month period ended June 30, 2022, the Company raised $0.5 million of proceeds from warrant exercises. The Company will need to continue to raise capital in order to provide funding for its operations and FDA approval process. If sufficient capital cannot be raised, the Company will continue its plans of curtailing operations by reducing discretionary spending and staffing levels and attempting to operate by only pursuing activities for which it has external financial support. However, there can be no assurance that such external financial support will be sufficient to maintain even limited operations or that the Company will be able to raise additional funds on acceptable terms, or at all. In such a case, the Company might be required to enter into unfavorable agreements or, if that is not possible, be unable to continue operations, and to the extent practicable, liquidate and/or file for bankruptcy protection.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company had warrants exercisable for approximately 24.7 million shares of its common stock outstanding at June 30, 2022, with exercise prices ranging between $0.15 and $0.80 per share. Exercises of in-the-money warrants would generate a total of approximately $4.2 million in cash, assuming full exercise, although the Company cannot be assured that holders will exercise any warrants. Management may obtain additional funds through the public or private sale of debt or equity, and grants, if available.</p>
CY2021Q4	gthp	Decrease In Authorized Common Share DecreaseInAuthorizedCommonShare	500000000	shares
CY2022Q2	gthp	Accumulated Deficit AccumulatedDeficit	-144400000	usd
CY2022Q2	gthp	Working Capital WorkingCapital	-4900000	usd
	gthp	Net Loss Including Preferred Dividend NetLossIncludingPreferredDividend	2100000	usd
CY2022Q2	gthp	Total Stockholders Deficits TotalStockholdersDeficits	-5800000	usd
	gthp	Proceeds From Exercise Of Warrants ProceedsFromExerciseOfWarrants	500000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation and input variables for Black-Scholes, Monte Carlo simulations and binomial calculations. The Company uses the Monte Carlo simulations and binomial calculations in the calculation of the fair value of the warrant liabilities and the valuation of embedded conversion options and freestanding warrants.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company, from time to time during the years covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk.</p>
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	1252000	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1255000	usd
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	70000	usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	69000	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	32000	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	32000	usd
CY2022Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	785000	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	785000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	569000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	571000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1793000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1761000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1748000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1747000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	45000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.30
CY2022Q2	gthp	Common Shares For Warrants Exercised CommonSharesForWarrantsExercised	5127923	shares
CY2021Q4	gthp	Common Shares For Warrants Exercised CommonSharesForWarrantsExercised	2193599	shares
CY2022Q2	gthp	Pending Issuance Of The Common Shares PendingIssuanceOfTheCommonShares	351000	shares
CY2021Q4	gthp	Pending Issuance Of The Common Shares PendingIssuanceOfTheCommonShares	2193599	shares
CY2022Q2	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	544000	usd
CY2021Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	621000	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	53000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	98000	usd
CY2022Q2	gthp	Accrued Stock Subscription Payable AccruedStockSubscriptionPayable	0	usd
CY2021Q4	gthp	Accrued Stock Subscription Payable AccruedStockSubscriptionPayable	351000	usd
CY2022Q2	us-gaap	Interest Payable Current InterestPayableCurrent	211000	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	261000	usd
CY2022Q2	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	41000	usd
CY2021Q4	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	39000	usd
CY2022Q2	us-gaap	Dividends Payable Current DividendsPayableCurrent	327000	usd
CY2021Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	349000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	30000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	49000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1206000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1768000	usd
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	512557	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	337315	usd
CY2022Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	155046	usd
CY2021Q4	gthp	Accounts Receivable Net Of Allowance AccountsReceivableNetOfAllowance	125584	usd
CY2022Q2	us-gaap	Notes Payable NotesPayable	29462	usd
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	171153	usd
CY2022Q2	gthp	Accounts Receivable Net Of Allowance AccountsReceivableNetOfAllowance	125584	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	45569	usd
CY2022Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	61600000	usd
	gthp	Warrants Warrants	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at the date of issuance is estimated using the Black-Scholes Model. The fair value of warrants classified as liabilities at the date of issuance is estimated using the Monte Carlo Simulation or Binomial model.</p>
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	-24000	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	-32000	usd
	gthp	Summary Of Changes To Level3 Instruments SummaryOfChangesToLevel3Instruments	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>(in thousands)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Senior Secured </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Derivative</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Balance, December 31, 2021</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(32</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(32</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Change in fair value during the period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Balance, June 30, 2022</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(24</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(24</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr></tbody></table>
CY2022Q2	gthp	Common Stock Shares Authorized Shares CommonStockSharesAuthorizedShares	500000000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	gthp	Common Stocks Shares Issued CommonStocksSharesIssued	27583473	shares
CY2021Q4	gthp	Common Stocks Shares Issued CommonStocksSharesIssued	13673583	shares
	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	13909890	shares
	gthp	Schedule Common Stock Issued Table Textblock ScheduleCommonStockIssuedTableTextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Number of </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issuance of common stock for warrants exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,127,923</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issuance of common stock for payment of Series D Preferred dividends</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">48,397</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issuance of common stock for payment of Series E Preferred dividends</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">62,662</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issuance of common stock for payment of Series F Preferred dividends</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">162,436</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issuance of common stock for payment of Series F-2 Preferred dividends</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">114,304</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issuance of common stock for payment of interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">121,262</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issuance of common stock for Series F one-time 15% dividend</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">255,401</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issuance of common stock for Series F-2 one-time 15% dividend</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">368,505</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Conversion of Series D Preferred stock to common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">975,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Conversion of Series E Preferred stock to common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,390,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Conversion of Series F Preferred stock to common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,420,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Conversion of Series F-2 Preferred stock to common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,864,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issued during the six months ended June 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">13,909,890</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Summary table of common stock share transactions:</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Shares outstanding at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,673,583</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issued in 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,909,890</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Shares outstanding at June 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">27,583,473</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
	gthp	I Ssuanceofcommonstockforwarrantsexercised ISsuanceofcommonstockforwarrantsexercised	5127923	shares
	gthp	Stock Issued During Period Shares Issued For Series D Dividends StockIssuedDuringPeriodSharesIssuedForSeriesDDividends	48397	shares
	gthp	Stock Issued During Period Shares Issued For Series F Dividends StockIssuedDuringPeriodSharesIssuedForSeriesFDividends	62662	shares
	gthp	Stockissuedduringperiodsharesissuedforseriesf Dividends StockissuedduringperiodsharesissuedforseriesfDividends	162436	shares
	gthp	Stock Issued During Period Shares Issued For Series F2 Dividends StockIssuedDuringPeriodSharesIssuedForSeriesF2Dividends	114304	shares
	gthp	Stock Issued During Period Shares Issued For Payment Of Interest StockIssuedDuringPeriodSharesIssuedForPaymentOfInterest	121262	shares
	gthp	Stock Issued During Period Shares Issued For Series F One Time Dividend StockIssuedDuringPeriodSharesIssuedForSeriesFOneTimeDividend	255401	shares
	gthp	Stock Issued During Period Shares Issued For Series F2 One Time Dividend StockIssuedDuringPeriodSharesIssuedForSeriesF2OneTimeDividend	368505	shares
	gthp	Conversion Of Stock D Shares Issued1 ConversionOfStockDSharesIssued1	975000	shares
	gthp	Conversion Of Stock E Shares Issued1 ConversionOfStockESharesIssued1	3390000	shares
	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	1420000	shares
	gthp	Conversion Of Stock Shares F2 Issued1 ConversionOfStockSharesF2Issued1	1864000	shares
	gthp	Stock Issued During Period StockIssuedDuringPeriod	13909890	shares
CY2020	gthp	Shares Outstanding One SharesOutstandingOne	13673583	shares
	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	13909890	shares
	gthp	Shares Outstanding One SharesOutstandingOne	27583473	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
	gthp	Fair Value Assumption Expected Dividend Rate FairValueAssumptionExpectedDividendRate	0.0000	pure
CY2021Q4	gthp	Notes Payable In Default NotesPayableInDefault	88000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	27669634	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.29
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	2934324	shares
	gthp	Share Based Compensation Arrangements By Share Based Payment Award Options Exercised In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice	0.17
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	24735310	shares
CY2022Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	28285	usd
CY2022Q2	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.10	pure
	gthp	Outstanding End OutstandingEnd	1500000	shares
	gthp	Weighted Average Remaining Contractual Life Outstanding WeightedAverageRemainingContractualLifeOutstanding	P8Y
	gthp	Agrregate Intrensic Value Outstanding AgrregateIntrensicValueOutstanding	0	usd
	gthp	Number Of Shares Exercisable NumberOfSharesExercisable	1136182	shares
CY2022Q2	gthp	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Ending Balance SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceEndingBalance	0.49
	gthp	Weighted Average Remaining Contractual Life Exercisable WeightedAverageRemainingContractualLifeExercisable	P8Y
	gthp	Agrregate Intrensic Value Exercisable AgrregateIntrensicValueExercisable	0	usd
CY2022Q2	gthp	Unrecognized Stock Based Compensation Expense UnrecognizedStockBasedCompensationExpense	175647	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.47
	gthp	Expected Term Years ExpectedTermYears	P10Y
	gthp	Fair Value Assumption Expected Volatility Rate FairValueAssumptionExpectedVolatilityRate	1.5312	pure
	gthp	Fair Value Assumption Risk Free Interest Rate FairValueAssumptionRiskFreeInterestRate	0.0098	pure
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	338000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	360000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	55000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	112000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	115000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	118000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	50000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	450000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	90000	usd
CY2022Q2	gthp	Operating Lease Liability1 OperatingLeaseLiability1	-360000	usd
CY2022Q2	gthp	Notes Payable In Default NotesPayableInDefault	28000	usd
	gthp	Weighted Average Remaining Lease Term Years WeightedAverageRemainingLeaseTermYears	P3Y10M24D
	gthp	Weighted Average Discount Rateoperating Lease WeightedAverageDiscountRateoperatingLease	0.114	pure
CY2016Q2	gthp	Royalty Percent RoyaltyPercent	0.20	pure
CY2020Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5000000	shares
CY2020Q1	gthp	Warrants Broken Into Four Tranches WarrantsBrokenIntoFourTranches	1250000	shares
CY2020Q1	us-gaap	Share Price SharePrice	0.25
CY2021Q4	gthp	Financing Agreement Amount FinancingAgreementAmount	1000000	usd
CY2019Q3	gthp	Consideration Received ConsiderationReceived	885144	usd
CY2019Q3	gthp	Escrow Agent Rate Per Share EscrowAgentRatePerShare	1.90
CY2022Q2	gthp	Short Term Notes Payable ShortTermNotesPayable	28285	usd
CY2021Q4	gthp	Short Term Notes Payable ShortTermNotesPayable	87615	usd
	gthp	Annual Interest Rate Description One AnnualInterestRateDescriptionOne	The notes carry annual interest rates between 4.3% and 16%, or 18% in the event of default
CY2021Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	39900	usd
CY2020Q2	us-gaap	Investment Interest Rate InvestmentInterestRate	0.24	pure
CY2022Q2	us-gaap	Principal Amount Outstanding On Loans Securitized PrincipalAmountOutstandingOnLoansSecuritized	625444	usd
CY2021Q4	us-gaap	Principal Amount Outstanding On Loans Securitized PrincipalAmountOutstandingOnLoansSecuritized	400000	usd
CY2022Q2	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	13760	usd
CY2021Q4	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	64778	usd
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	13586	usd
CY2022Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	23825	usd
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	31889	usd
CY2022Q2	gthp	Auctus Tranche2 Default Penalty AuctusTranche2DefaultPenalty	225000	usd
CY2021Q4	gthp	Auctus Tranche2 Default Penalty AuctusTranche2DefaultPenalty	0	usd
CY2022Q2	gthp	Debt Discount And Issuance Costs To Be Amortized DebtDiscountAndIssuanceCostsToBeAmortized	0	usd
CY2021Q4	gthp	Debt Discount And Issuance Costs To Be Amortized DebtDiscountAndIssuanceCostsToBeAmortized	-14000	usd
CY2022Q2	gthp	Convertible Notes Payable Short Term ConvertibleNotesPayableShortTerm	1136000	usd
CY2021Q4	gthp	Convertible Notes Payable Short Term ConvertibleNotesPayableShortTerm	897000	usd
CY2022Q2	us-gaap	Repurchase Agreements Interest Expense Amount RepurchaseAgreementsInterestExpenseAmount	29776	usd
CY2022Q2	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	31285	usd
CY2022Q2	us-gaap	Accretion Expense AccretionExpense	8939	usd
CY2022Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	70000	usd
CY2022Q2	us-gaap	Direct Financing Lease Revenue DirectFinancingLeaseRevenue	4000000	usd
CY2022Q2	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	490278	usd
CY2022Q2	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	101674	usd
	gthp	Bond Payable Discount And Unamortized Debt Issuance Costs BondPayableDiscountAndUnamortizedDebtIssuanceCosts	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30, 2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, 2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">10% Senior Unsecured Convertible Debentures</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,130</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,130</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Debt Issuance costs to be amortized</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(55</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(69</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Debt Discount</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:right;">(191</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:right;">(241</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><strong>Long-term convertible debt</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">884</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">820</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q2	gthp	Senior Unsecured Convertible Debentures SeniorUnsecuredConvertibleDebentures	1130000	usd
CY2021Q4	gthp	Senior Unsecured Convertible Debentures SeniorUnsecuredConvertibleDebentures	1130000	usd
CY2022Q2	gthp	Debt Issuance Costs Amortized DebtIssuanceCostsAmortized	-55000	usd
CY2021Q4	gthp	Debt Issuance Costs Amortized DebtIssuanceCostsAmortized	-69000	usd
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	191000	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	241000	usd
CY2022Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	884000	usd
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	820000	usd
CY2022Q2	gthp	Current Portion Of Long Term Debt CurrentPortionOfLongTermDebt	47052	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2061000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1871000	usd
	us-gaap	Weighted Average Number Basic Shares Outstanding Adjustment Pro Forma WeightedAverageNumberBasicSharesOutstandingAdjustmentProForma	23526	shares
	us-gaap	Weighted Average Number Basic Shares Outstanding Adjustment Pro Forma WeightedAverageNumberBasicSharesOutstandingAdjustmentProForma	13226	shares
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.09
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.14
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	23526	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	13226	shares
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.09
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.14
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28244	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	37466	shares
	gthp	Decrease Net Income Loss DecreaseNetIncomeLoss	74785	usd
	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	74785	usd
	gthp	Loss On Extinguishment Of Debt LossOnExtinguishmentOfDebt	179000	usd
CY2022Q2	gthp	Dividend Percentage DividendPercentage	0.10	pure
CY2022Q3	us-gaap	Line Of Credit Facility Average Outstanding Amount LineOfCreditFacilityAverageOutstandingAmount	114086	usd

Files In Submission

Name	View Source	Status
0001477932-22-006064-index-headers.html	Edgar Link	pending
0001477932-22-006064-index.html	Edgar Link	pending
0001477932-22-006064.txt	Edgar Link	pending
0001477932-22-006064-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
gthp-20220630.xsd	Edgar Link	pending
gthp_10q.htm	Edgar Link	pending
gthp_ex31.htm	Edgar Link	pending
gthp_ex32.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
gthp-20220630_cal.xml	Edgar Link	unprocessable
gthp-20220630_def.xml	Edgar Link	unprocessable
gthp-20220630_lab.xml	Edgar Link	unprocessable
gthp-20220630_pre.xml	Edgar Link	unprocessable
gthp_10q_htm.xml	Edgar Link	completed
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GTHP
GUIDED THERAPEUTICS INC Stock $gthp

2022 Q3 Form 10-Q Financial Statement

#000147793222006064 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GTHP GUIDED THERAPEUTICS INC Stock $gthp

2022 Q3 Form 10-Q Financial Statement

#000147793222006064 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GTHP
GUIDED THERAPEUTICS INC Stock $gthp